Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations.
Khor CC, Winter S, Sutiman N, Mürdter TE, Chen S, Lim JSL, Li Z, Li J, Sim KS, Ganchev B, Eccles D, Eccles B, Tapper W, Zgheib NK, Tfayli A, Ng RCH, Yap YS, Lim E, Wong M, Wong NS, Ang PCS, Dent R, Tremmel R, Klein K, Schaeffeler E, Zhou Y, Lauschke VM, Eichelbaum M, Schwab M, Brauch HB, Chowbay B, Schroth W. Khor CC, et al. Among authors: dent r. Clin Pharmacol Ther. 2023 Mar;113(3):712-723. doi: 10.1002/cpt.2846. Epub 2023 Jan 31. Clin Pharmacol Ther. 2023. PMID: 36629403
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.
Dent R, André F, Gonçalves A, Martin M, Schmid P, Schütz F, Kümmel S, Swain SM, Bilici A, Loirat D, Villalobos Valencia R, Im SA, Park YH, De Laurentis M, Colleoni M, Guarneri V, Bianchini G, Li H, Kirchmayer Machackova Z, Mouta J, Deurloo R, Gan X, Fan M, Mani A, Swat A, Cortés J. Dent R, et al. Ann Oncol. 2024 May 7:S0923-7534(24)00107-8. doi: 10.1016/j.annonc.2024.04.001. Online ahead of print. Ann Oncol. 2024. PMID: 38755096 Free article.
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent R, McArthur H, Kümmel S, Bergh J, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Zhu Y, Pan W, Tryfonidis K, Schmid P. Pusztai L, et al. Among authors: dent r. Ann Oncol. 2024 May;35(5):429-436. doi: 10.1016/j.annonc.2024.02.002. Epub 2024 Feb 17. Ann Oncol. 2024. PMID: 38369015 Clinical Trial.
The weapons of mass destruction-civil support team PA.
Radi JK, Dent RA, Allen CA, Anderson JA, Atkins JB, Kozlik J. Radi JK, et al. Among authors: dent ra. JAAPA. 2024 Feb 1;37(2):1-5. doi: 10.1097/01.JAA.0000995656.06965.36. JAAPA. 2024. PMID: 38270662
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
Tan TJ, Sammons S, Im YH, She L, Mundy K, Bigelow R, Traina TA, Anders C, Yeong J, Renzulli E, Kim SB, Dent R. Tan TJ, et al. Among authors: dent r. Clin Cancer Res. 2024 Apr 1;30(7):1240-1247. doi: 10.1158/1078-0432.CCR-23-2513. Clin Cancer Res. 2024. PMID: 38236575 Free PMC article. Clinical Trial.
358 results